10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

TLX (TELIX Pharmaceuticals Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze TELIX Pharmaceuticals Ltd together

I guess you are interested in TELIX Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – TELIX Pharmaceuticals Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – TELIX Pharmaceuticals Ltd’s Price Targets

I'm going to help you getting a better view of TELIX Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about TELIX Pharmaceuticals Ltd

I send you an email if I find something interesting about TELIX Pharmaceuticals Ltd.

1. Quick Overview

1.1. Quick analysis of TELIX Pharmaceuticals Ltd (30 sec.)










1.2. What can you expect buying and holding a share of TELIX Pharmaceuticals Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
37.5%

What is your share worth?

Current worth
A$1.65
Expected worth in 1 year
A$6.45
How sure are you?
87.5%

+ What do you gain per year?

Total Gains per Share
A$4.80
Return On Investment
19.6%

For what price can you sell your share?

Current Price per Share
A$24.47
Expected price per share
A$22.38 - A$27.40
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of TELIX Pharmaceuticals Ltd (5 min.)




Live pricePrice per Share (EOD)
A$24.47
Intrinsic Value Per Share
A$0.21 - A$2.62
Total Value Per Share
A$1.86 - A$4.27

2.2. Growth of TELIX Pharmaceuticals Ltd (5 min.)




Is TELIX Pharmaceuticals Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$371.6m$97.4m$274.2m73.8%

How much money is TELIX Pharmaceuticals Ltd making?

Current yearPrevious yearGrowGrow %
Making money$32.6m$3.4m$29.2m89.6%
Net Profit Margin6.4%1.0%--

How much money comes from the company's main activities?

2.3. Financial Health of TELIX Pharmaceuticals Ltd (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#162 / 872

Most Revenue
#33 / 872

Most Profit
#54 / 872

Most Efficient
#138 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of TELIX Pharmaceuticals Ltd?

Welcome investor! TELIX Pharmaceuticals Ltd's management wants to use your money to grow the business. In return you get a share of TELIX Pharmaceuticals Ltd.

First you should know what it really means to hold a share of TELIX Pharmaceuticals Ltd. And how you can make/lose money.

Speculation

The Price per Share of TELIX Pharmaceuticals Ltd is A$24.47. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of TELIX Pharmaceuticals Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in TELIX Pharmaceuticals Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$1.65. Based on the TTM, the Book Value Change Per Share is A$1.20 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.20 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of TELIX Pharmaceuticals Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.090.4%0.090.4%0.010.0%-0.03-0.1%-0.07-0.3%-0.05-0.2%
Usd Book Value Change Per Share0.793.2%0.793.2%0.130.5%0.361.5%0.190.8%0.130.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.110.4%0.080.3%0.060.3%
Usd Total Gains Per Share0.793.2%0.793.2%0.130.5%0.471.9%0.271.1%0.200.8%
Usd Price Per Share16.10-16.10-6.59-9.15-7.00-4.60-
Price to Earnings Ratio170.18-170.18-647.48-264.76-146.77-83.37-
Price-to-Total Gains Ratio20.49-20.49-50.54-26.96-15.17-20.90-
Price to Book Ratio14.95-14.95-22.66-22.41-159.06-101.37-
Price-to-Total Gains Ratio20.49-20.49-50.54-26.96-15.17-20.90-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share16.005827
Number of shares62
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.08
Usd Book Value Change Per Share0.790.19
Usd Total Gains Per Share0.790.27
Gains per Quarter (62 shares)48.7116.55
Gains per Year (62 shares)194.8666.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10195185204756
203903803993122
3058557559140188
4077977079186254
5097496598233320
6011691160118279386
7013641355138326452
8015591550157372518
9017541745177419584
10019491940197465650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%2.01.00.066.7%2.03.00.040.0%2.06.00.025.0%2.06.00.025.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%7.01.00.087.5%7.01.00.087.5%
Dividend per Share0.00.01.00.0%1.00.02.033.3%2.00.03.040.0%3.00.05.037.5%3.00.05.037.5%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%7.01.00.087.5%7.01.00.087.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of TELIX Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.2011.2010%0.199+502%0.545+120%0.287+319%0.206+484%
Book Value Per Share--1.6461.6460%0.445+270%0.779+111%0.517+218%0.388+324%
Current Ratio--2.7762.7760%1.428+94%2.076+34%2.435+14%6.973-60%
Debt To Asset Ratio--0.6250.6250%0.6260%0.645-3%0.683-8%0.509+23%
Debt To Equity Ratio--1.6691.6690%1.6750%1.858-10%11.168-85%7.098-76%
Dividend Per Share----0%-0%0.168-100%0.121-100%0.096-100%
Enterprise Value--8257204680.0008257204680.0000%3247863920.000+154%4625468693.333+79%3529028160.000+134%2331338614.125+254%
Eps--0.1450.1450%0.016+829%-0.050+135%-0.105+173%-0.084+158%
Ev To Ebitda Ratio--89.22289.2220%141.421-37%68.366+31%28.254+216%10.058+787%
Ev To Sales Ratio--10.54310.5430%6.463+63%10.606-1%120.743-91%314.001-97%
Free Cash Flow Per Share--0.0260.0260%0.039-33%-0.056+314%-0.069+364%-0.062+337%
Free Cash Flow To Equity Per Share--1.8771.8770%0.070+2599%0.746+152%0.434+332%0.289+550%
Gross Profit Margin---1.308-1.3080%-9.529+629%-3.227+147%-1.516+16%-0.562-57%
Intrinsic Value_10Y_max--2.623----------
Intrinsic Value_10Y_min--0.212----------
Intrinsic Value_1Y_max--0.013----------
Intrinsic Value_1Y_min---0.047----------
Intrinsic Value_3Y_max--0.229----------
Intrinsic Value_3Y_min---0.082----------
Intrinsic Value_5Y_max--0.675----------
Intrinsic Value_5Y_min---0.053----------
Market Cap8190696280.000-4%8495076680.0008495076680.0000%3374017920.000+152%4767512693.333+78%3632381160.000+134%2388228435.000+256%
Net Profit Margin--0.0640.0640%0.010+515%-0.192+401%-3.957+6309%-14.307+22547%
Operating Margin--0.1050.1050%0.032+225%-0.159+251%-3.988+3903%-22.583+21636%
Operating Ratio--0.8950.8950%0.8980%1.084-17%5.079-82%24.604-96%
Pb Ratio14.865-1%14.95114.9510%22.658-34%22.409-33%159.064-91%101.372-85%
Pe Ratio169.209-1%170.177170.1770%647.480-74%264.759-36%146.774+16%83.372+104%
Price Per Share24.470-1%24.61024.6100%10.080+144%13.987+76%10.698+130%7.039+250%
Price To Free Cash Flow Ratio938.841-1%944.212944.2120%257.755+266%390.234+142%380.076+148%229.215+312%
Price To Total Gains Ratio20.371-1%20.48820.4880%50.543-59%26.962-24%15.166+35%20.896-2%
Quick Ratio--2.6272.6270%1.194+120%1.880+40%2.277+15%6.812-61%
Return On Assets--0.0330.0330%0.013+152%-0.118+458%-0.272+926%-0.242+835%
Return On Equity--0.0880.0880%0.035+151%-0.393+547%-7.811+8991%-4.980+5769%
Total Gains Per Share--1.2011.2010%0.199+502%0.713+69%0.408+194%0.302+298%
Usd Book Value--371668123.300371668123.3000%97402685.100+282%174269682.667+113%115503594.400+222%86328788.861+331%
Usd Book Value Change Per Share--0.7860.7860%0.130+502%0.357+120%0.188+319%0.135+484%
Usd Book Value Per Share--1.0771.0770%0.291+270%0.509+111%0.338+218%0.254+324%
Usd Dividend Per Share----0%-0%0.110-100%0.079-100%0.063-100%
Usd Enterprise Value--5401037581.1885401037581.1880%2124427790.072+154%3025519072.309+79%2308337319.456+134%1524928587.499+254%
Usd Eps--0.0950.0950%0.010+829%-0.033+135%-0.069+173%-0.055+158%
Usd Free Cash Flow--5884937.7005884937.7000%8562169.000-31%-12154050.133+307%-15014603.860+355%-13520150.602+330%
Usd Free Cash Flow Per Share--0.0170.0170%0.026-33%-0.036+314%-0.045+364%-0.040+337%
Usd Free Cash Flow To Equity Per Share--1.2281.2280%0.045+2599%0.488+152%0.284+332%0.189+550%
Usd Market Cap5357534436.748-4%5556629656.3885556629656.3880%2206945121.472+152%3118430052.709+78%2375940516.756+134%1562140219.334+256%
Usd Price Per Share16.006-1%16.09716.0970%6.593+144%9.149+76%6.998+130%4.604+250%
Usd Profit--32652017.90032652017.9000%3408515.100+858%-10672513.633+133%-22807943.720+170%-18185610.344+156%
Usd Revenue--512295698.700512295698.7000%328715992.700+56%315243495.000+63%190821770.380+168%119597492.568+328%
Usd Total Gains Per Share--0.7860.7860%0.130+502%0.466+69%0.267+194%0.198+298%
 EOD+4 -4MRQTTM+0 -0YOY+31 -73Y+34 -65Y+34 -610Y+29 -11

3.3 Fundamental Score

Let's check the fundamental score of TELIX Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15169.209
Price to Book Ratio (EOD)Between0-114.865
Net Profit Margin (MRQ)Greater than00.064
Operating Margin (MRQ)Greater than00.105
Quick Ratio (MRQ)Greater than12.627
Current Ratio (MRQ)Greater than12.776
Debt to Asset Ratio (MRQ)Less than10.625
Debt to Equity Ratio (MRQ)Less than11.669
Return on Equity (MRQ)Greater than0.150.088
Return on Assets (MRQ)Greater than0.050.033
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of TELIX Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.548
Ma 20Greater thanMa 5024.662
Ma 50Greater thanMa 10025.614
Ma 100Greater thanMa 20026.461
OpenGreater thanClose25.740
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About TELIX Pharmaceuticals Ltd

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases. The company operates through three segments: Therapeutics, Precision Medicine, and Telix Manufacturing Solutions. It offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. The company's products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX007-CDx, a cold kit for the preparation of imaging for prostate cancer; TLX66-CDx to treat bone marrow conditioning. It also TLX250 for the treatment of clear cell renal cell carcinoma; TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning. In addition, the company develops TLX300 for the treatment of soft tissue sarcoma; TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX090, a bone-seeking agent for bone metastases and pain palliation. Further, it operates in Australia, New Zealand, Belgium, Japan, Switzerland, Germany, the United Kingdom, Canada, Singapore, Austria, Spain, France, and the United States. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

Fundamental data was last updated by Penke on 2025-07-09 03:09:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit TELIX Pharmaceuticals Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare TELIX Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 6.4% means that $0.06 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of TELIX Pharmaceuticals Ltd:

  • The MRQ is 6.4%. The company is making a profit. +1
  • The TTM is 6.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.4%TTM6.4%0.0%
TTM6.4%YOY1.0%+5.3%
TTM6.4%5Y-395.7%+402.1%
5Y-395.7%10Y-1,430.7%+1,035.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4%-92.7%+99.1%
TTM6.4%-140.3%+146.7%
YOY1.0%-196.4%+197.4%
3Y-19.2%-248.5%+229.3%
5Y-395.7%-343.4%-52.3%
10Y-1,430.7%-496.2%-934.5%
4.3.1.2. Return on Assets

Shows how efficient TELIX Pharmaceuticals Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare TELIX Pharmaceuticals Ltd to the Biotechnology industry mean.
  • 3.3% Return on Assets means that TELIX Pharmaceuticals Ltd generated $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of TELIX Pharmaceuticals Ltd:

  • The MRQ is 3.3%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.3%TTM3.3%0.0%
TTM3.3%YOY1.3%+2.0%
TTM3.3%5Y-27.2%+30.5%
5Y-27.2%10Y-24.2%-3.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3%-11.6%+14.9%
TTM3.3%-11.6%+14.9%
YOY1.3%-11.4%+12.7%
3Y-11.8%-11.8%+0.0%
5Y-27.2%-12.0%-15.2%
10Y-24.2%-13.7%-10.5%
4.3.1.3. Return on Equity

Shows how efficient TELIX Pharmaceuticals Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare TELIX Pharmaceuticals Ltd to the Biotechnology industry mean.
  • 8.8% Return on Equity means TELIX Pharmaceuticals Ltd generated $0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of TELIX Pharmaceuticals Ltd:

  • The MRQ is 8.8%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 8.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ8.8%TTM8.8%0.0%
TTM8.8%YOY3.5%+5.3%
TTM8.8%5Y-781.1%+789.9%
5Y-781.1%10Y-498.0%-283.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.8%-13.6%+22.4%
TTM8.8%-15.0%+23.8%
YOY3.5%-14.5%+18.0%
3Y-39.3%-16.9%-22.4%
5Y-781.1%-17.5%-763.6%
10Y-498.0%-19.9%-478.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of TELIX Pharmaceuticals Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient TELIX Pharmaceuticals Ltd is operating .

  • Measures how much profit TELIX Pharmaceuticals Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare TELIX Pharmaceuticals Ltd to the Biotechnology industry mean.
  • An Operating Margin of 10.5% means the company generated $0.10  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of TELIX Pharmaceuticals Ltd:

  • The MRQ is 10.5%. The company is operating less efficient.
  • The TTM is 10.5%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ10.5%TTM10.5%0.0%
TTM10.5%YOY3.2%+7.3%
TTM10.5%5Y-398.8%+409.3%
5Y-398.8%10Y-2,258.3%+1,859.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.5%-229.2%+239.7%
TTM10.5%-249.0%+259.5%
YOY3.2%-208.5%+211.7%
3Y-15.9%-223.8%+207.9%
5Y-398.8%-346.1%-52.7%
10Y-2,258.3%-475.5%-1,782.8%
4.3.2.2. Operating Ratio

Measures how efficient TELIX Pharmaceuticals Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.90 means that the operating costs are $0.90 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of TELIX Pharmaceuticals Ltd:

  • The MRQ is 0.895. The company is less efficient in keeping operating costs low.
  • The TTM is 0.895. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.895TTM0.8950.000
TTM0.895YOY0.898-0.003
TTM0.8955Y5.079-4.184
5Y5.07910Y24.604-19.525
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8952.110-1.215
TTM0.8952.684-1.789
YOY0.8983.096-2.198
3Y1.0843.652-2.568
5Y5.0794.745+0.334
10Y24.6046.614+17.990
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of TELIX Pharmaceuticals Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if TELIX Pharmaceuticals Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.78 means the company has $2.78 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of TELIX Pharmaceuticals Ltd:

  • The MRQ is 2.776. The company is able to pay all its short-term debts. +1
  • The TTM is 2.776. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.776TTM2.7760.000
TTM2.776YOY1.428+1.347
TTM2.7765Y2.435+0.341
5Y2.43510Y6.973-4.539
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7763.661-0.885
TTM2.7763.846-1.070
YOY1.4284.140-2.712
3Y2.0764.688-2.612
5Y2.4355.746-3.311
10Y6.9736.147+0.826
4.4.3.2. Quick Ratio

Measures if TELIX Pharmaceuticals Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare TELIX Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 2.63 means the company can pay off $2.63 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of TELIX Pharmaceuticals Ltd:

  • The MRQ is 2.627. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.627. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.627TTM2.6270.000
TTM2.627YOY1.194+1.433
TTM2.6275Y2.277+0.350
5Y2.27710Y6.812-4.535
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6272.826-0.199
TTM2.6273.182-0.555
YOY1.1943.786-2.592
3Y1.8804.311-2.431
5Y2.2775.703-3.426
10Y6.8126.454+0.358
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of TELIX Pharmaceuticals Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of TELIX Pharmaceuticals Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare TELIX Pharmaceuticals Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.63 means that TELIX Pharmaceuticals Ltd assets are financed with 62.5% credit (debt) and the remaining percentage (100% - 62.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of TELIX Pharmaceuticals Ltd:

  • The MRQ is 0.625. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.625. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.625TTM0.6250.000
TTM0.625YOY0.626-0.001
TTM0.6255Y0.683-0.058
5Y0.68310Y0.509+0.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6250.329+0.296
TTM0.6250.349+0.276
YOY0.6260.331+0.295
3Y0.6450.340+0.305
5Y0.6830.349+0.334
10Y0.5090.379+0.130
4.5.4.2. Debt to Equity Ratio

Measures if TELIX Pharmaceuticals Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare TELIX Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 166.9% means that company has $1.67 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of TELIX Pharmaceuticals Ltd:

  • The MRQ is 1.669. The company is just able to pay all its debts with equity.
  • The TTM is 1.669. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.669TTM1.6690.000
TTM1.669YOY1.675-0.006
TTM1.6695Y11.168-9.499
5Y11.16810Y7.098+4.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6690.379+1.290
TTM1.6690.437+1.232
YOY1.6750.414+1.261
3Y1.8580.450+1.408
5Y11.1680.464+10.704
10Y7.0980.515+6.583
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings TELIX Pharmaceuticals Ltd generates.

  • Above 15 is considered overpriced but always compare TELIX Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A PE ratio of 170.18 means the investor is paying $170.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of TELIX Pharmaceuticals Ltd:

  • The EOD is 169.209. Based on the earnings, the company is expensive. -2
  • The MRQ is 170.177. Based on the earnings, the company is expensive. -2
  • The TTM is 170.177. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD169.209MRQ170.177-0.968
MRQ170.177TTM170.1770.000
TTM170.177YOY647.480-477.303
TTM170.1775Y146.774+23.404
5Y146.77410Y83.372+63.402
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD169.209-2.304+171.513
MRQ170.177-2.080+172.257
TTM170.177-2.564+172.741
YOY647.480-3.764+651.244
3Y264.759-3.773+268.532
5Y146.774-6.193+152.967
10Y83.372-6.833+90.205
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of TELIX Pharmaceuticals Ltd:

  • The EOD is 938.841. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 944.212. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 944.212. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD938.841MRQ944.212-5.371
MRQ944.212TTM944.2120.000
TTM944.212YOY257.755+686.457
TTM944.2125Y380.076+564.136
5Y380.07610Y229.215+150.861
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD938.841-3.132+941.973
MRQ944.212-2.705+946.917
TTM944.212-3.666+947.878
YOY257.755-4.405+262.160
3Y390.234-5.059+395.293
5Y380.076-8.477+388.553
10Y229.215-9.304+238.519
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of TELIX Pharmaceuticals Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 14.95 means the investor is paying $14.95 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of TELIX Pharmaceuticals Ltd:

  • The EOD is 14.865. Based on the equity, the company is expensive. -2
  • The MRQ is 14.951. Based on the equity, the company is expensive. -2
  • The TTM is 14.951. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD14.865MRQ14.951-0.085
MRQ14.951TTM14.9510.000
TTM14.951YOY22.658-7.707
TTM14.9515Y159.064-144.114
5Y159.06410Y101.372+57.692
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD14.8651.953+12.912
MRQ14.9511.843+13.108
TTM14.9512.112+12.839
YOY22.6582.441+20.217
3Y22.4092.494+19.915
5Y159.0643.661+155.403
10Y101.3724.311+97.061
4.6.2. Total Gains per Share

2.4. Latest News of TELIX Pharmaceuticals Ltd

Does TELIX Pharmaceuticals Ltd still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from TELIX Pharmaceuticals Ltd to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-29
19:28
Telix Pharmaceuticals (TLX) Announces That US FDA Approves Label Expansion for IlluccixRead
2025-06-20
02:18
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of TELIX Pharmaceuticals Ltd.

4.8.2. Funds holding TELIX Pharmaceuticals Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-02-28SPDR Portfolio Developed World ex-US ETF0.04-101786--
2021-02-28SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF0.029999999-97238--
Total 0.069999999019902400.0%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets1,516,431
Total Liabilities948,218
Total Stockholder Equity568,213
 As reported
Total Liabilities 948,218
Total Stockholder Equity+ 568,213
Total Assets = 1,516,431

Assets

Total Assets1,516,431
Total Current Assets918,564
Long-term Assets597,867
Total Current Assets
Cash And Cash Equivalents 710,346
Net Receivables 158,994
Inventory 38,144
Other Current Assets 11,080
Total Current Assets  (as reported)918,564
Total Current Assets  (calculated)918,564
+/-0
Long-term Assets
Property Plant Equipment 54,321
Goodwill 106,647
Long Term Investments 6,093
Intangible Assets 309,487
Long-term Assets Other 74,582
Long-term Assets  (as reported)597,867
Long-term Assets  (calculated)551,130
+/- 46,737

Liabilities & Shareholders' Equity

Total Current Liabilities330,912
Long-term Liabilities617,306
Total Stockholder Equity568,213
Total Current Liabilities
Short-term Debt 21,486
Short Long Term Debt 18,990
Accounts payable 68,698
Other Current Liabilities 180,903
Total Current Liabilities  (as reported)330,912
Total Current Liabilities  (calculated)290,077
+/- 40,835
Long-term Liabilities
Long term Debt 551,821
Capital Lease Obligations 10,637
Long-term Liabilities Other 30,406
Long-term Liabilities  (as reported)617,306
Long-term Liabilities  (calculated)592,864
+/- 24,442
Total Stockholder Equity
Retained Earnings -212,962
Accumulated Other Comprehensive Income 184,399
Other Stockholders Equity 596,776
Total Stockholder Equity (as reported)568,213
Total Stockholder Equity (calculated)568,213
+/-0
Other
Cash and Short Term Investments 710,346
Common Stock Shares Outstanding 345,188
Current Deferred Revenue11,248
Liabilities and Stockholders Equity 1,516,431
Net Debt -128,898
Net Invested Capital 1,139,024
Net Working Capital 587,652
Property Plant and Equipment Gross 63,609
Short Long Term Debt Total 581,448



5.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312000-12-311999-12-31
> Total Assets 
0
9,394
51,094
76,708
102,608
164,442
109,813
260,591
398,302
1,516,431
1,516,431398,302260,591109,813164,442102,60876,70851,0949,3940
   > Total Current Assets 
0
3,049
49,545
35,856
58,679
93,628
47,543
173,233
224,848
918,564
918,564224,848173,23347,54393,62858,67935,85649,5453,0490
       Cash And Cash Equivalents 
0
2,994
48,759
25,771
44,598
77,945
22,037
116,329
123,237
710,346
710,346123,237116,32922,03777,94544,59825,77148,7592,9940
       Net Receivables 
0
55
489
8,436
13,009
14,191
20,845
39,354
64,777
158,994
158,99464,77739,35420,84514,19113,0098,436489550
       Other Current Assets 
0
0
297
535
530
859
1,207
9,073
19,524
11,080
11,08019,5249,0731,20785953053529700
   > Long-term Assets 
0
6,345
1,549
40,852
43,929
70,814
62,270
87,358
173,454
597,867
597,867173,45487,35862,27070,81443,92940,8521,5496,3450
       Property Plant Equipment 
0
6,345
5
226
1,899
4,821
6,329
18,838
30,493
54,321
54,32130,49318,8386,3294,8211,89922656,3450
       Goodwill 
0
0
332
3,140
4,224
4,224
4,097
5,519
4,847
106,647
106,6474,8475,5194,0974,2244,2243,14033200
       Long Term Investments 
0
0
0
0
0
0
0
0
12,260
6,093
6,09312,26000000000
       Intangible Assets 
0
0
1,176
36,311
41,948
59,189
55,729
58,984
104,816
309,487
309,487104,81658,98455,72959,18941,94836,3111,17600
       Other Assets 
0
0
35
1,175
82
183
212
3,971
0
0
003,971212183821,1753500
> Total Liabilities 
0
352
1,801
23,804
31,877
84,444
106,171
178,435
249,391
948,218
948,218249,391178,435106,17184,44431,87723,8041,8013520
   > Total Current Liabilities 
0
352
1,468
8,242
10,625
19,956
37,982
85,556
157,408
330,912
330,912157,40885,55637,98219,95610,6258,2421,4683520
       Short-term Debt 
0
0
345
1,133
490
767
632
641
1,559
21,486
21,4861,5596416327674901,13334500
       Short Long Term Debt 
0
0
345
1,133
469
264
19
0
964
18,990
18,9909640192644691,13334500
       Accounts payable 
0
352
276
3,249
6,964
5,808
11,884
16,806
32,837
68,698
68,69832,83716,80611,8845,8086,9643,2492763520
       Other Current Liabilities 
0
0
847
216
3,171
10,146
19,323
55,849
100,509
180,903
180,903100,50955,84919,32310,1463,17121684700
   > Long-term Liabilities 
0
352
332
15,562
21,252
64,488
68,189
92,879
91,983
617,306
617,30691,98392,87968,18964,48821,25215,5623323520
       Long term Debt Total 
0
0
0
596
1,641
1,440
1,907
9,805
0
0
009,8051,9071,4401,641596000
       Other Liabilities 
0
0
332
14,966
20,261
57,409
67,766
79,985
0
0
0079,98567,76657,40920,26114,96633200
> Total Stockholder Equity
0
9,042
49,293
52,904
70,081
79,016
2,158
80,007
148,911
568,213
568,213148,91180,0072,15879,01670,08152,90449,2939,0420
   Common Stock
0
15,121
55,561
72,053
115,943
167,058
170,840
370,972
446,268
0
0446,268370,972170,840167,058115,94372,05355,56115,1210
   Retained Earnings Total Equity0000000000
   Accumulated Other Comprehensive Income 
0
0
109
1,059
2,212
4,919
4,789
-18,150
-33,692
184,399
184,399-33,692-18,1504,7894,9192,2121,05910900
   Capital Surplus 0000000000
   Treasury Stock0000000000
   Other Stockholders Equity 
0
0
109
1,059
2,212
4,919
4,789
-562
0
596,776
596,7760-5624,7894,9192,2121,05910900



5.3. Balance Sheets

Currency in AUD. All numbers in thousands.




5.4. Cash Flows

Currency in AUD. All numbers in thousands.




5.5. Income Statements

Currency in AUD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue783,207
Cost of Revenue-273,529
Gross Profit509,678509,678
 
Operating Income (+$)
Gross Profit509,678
Operating Expense-427,548
Operating Income82,13082,130
 
Operating Expense (+$)
Research Development194,637
Selling General Administrative117,661
Selling And Marketing Expenses115,196
Operating Expense427,548427,494
 
Net Interest Income (+$)
Interest Income10,862
Interest Expense-36,491
Other Finance Cost-445
Net Interest Income-26,074
 
Pretax Income (+$)
Operating Income82,130
Net Interest Income-26,074
Other Non-Operating Income Expenses0
Income Before Tax (EBT)56,056108,204
EBIT - interestExpense = 45,639
56,056
86,410
Interest Expense36,491
Earnings Before Interest and Taxes (EBIT)82,13092,547
Earnings Before Interest and Taxes (EBITDA)92,547
 
After tax Income (+$)
Income Before Tax56,056
Tax Provision-6,137
Net Income From Continuing Ops49,91949,919
Net Income49,919
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses701,077
Total Other Income/Expenses Net-26,07426,074
 

Technical Analysis of TELIX Pharmaceuticals Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of TELIX Pharmaceuticals Ltd. The general trend of TELIX Pharmaceuticals Ltd is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine TELIX Pharmaceuticals Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. TELIX Pharmaceuticals Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of TELIX Pharmaceuticals Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 24.73 < 26.25 < 27.40.

The bearish price targets are: 25.27 > 22.76 > 22.38.

Know someone who trades $TLX? Share this with them.👇

TELIX Pharmaceuticals Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of TELIX Pharmaceuticals Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

TELIX Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of TELIX Pharmaceuticals Ltd. The current macd is -0.33722598.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the TELIX Pharmaceuticals Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for TELIX Pharmaceuticals Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the TELIX Pharmaceuticals Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
TELIX Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartTELIX Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of TELIX Pharmaceuticals Ltd. The current adx is 29.62.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell TELIX Pharmaceuticals Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
TELIX Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of TELIX Pharmaceuticals Ltd. The current sar is 22.82.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
TELIX Pharmaceuticals Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of TELIX Pharmaceuticals Ltd. The current rsi is 46.55. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
TELIX Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartTELIX Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of TELIX Pharmaceuticals Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the TELIX Pharmaceuticals Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
TELIX Pharmaceuticals Ltd Daily Stochastic Oscillator ChartTELIX Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of TELIX Pharmaceuticals Ltd. The current cci is 37.38.

TELIX Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartTELIX Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of TELIX Pharmaceuticals Ltd. The current cmo is -4.59429677.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
TELIX Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartTELIX Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of TELIX Pharmaceuticals Ltd. The current willr is -45.01607717.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that TELIX Pharmaceuticals Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
TELIX Pharmaceuticals Ltd Daily Williams %R ChartTELIX Pharmaceuticals Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of TELIX Pharmaceuticals Ltd.

TELIX Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of TELIX Pharmaceuticals Ltd. The current atr is 0.97635787.

TELIX Pharmaceuticals Ltd Daily Average True Range (ATR) ChartTELIX Pharmaceuticals Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of TELIX Pharmaceuticals Ltd. The current obv is 54,577,400.

TELIX Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartTELIX Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of TELIX Pharmaceuticals Ltd. The current mfi is 37.58.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
TELIX Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartTELIX Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for TELIX Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-25BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

TELIX Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of TELIX Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.548
Ma 20Greater thanMa 5024.662
Ma 50Greater thanMa 10025.614
Ma 100Greater thanMa 20026.461
OpenGreater thanClose25.740
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of TELIX Pharmaceuticals Ltd with someone you think should read this too:
  • Are you bullish or bearish on TELIX Pharmaceuticals Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about TELIX Pharmaceuticals Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about TELIX Pharmaceuticals Ltd

I send you an email if I find something interesting about TELIX Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about TELIX Pharmaceuticals Ltd.

Receive notifications about TELIX Pharmaceuticals Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.